This article is more than 5 years old. Information may no longer be current.

Ista submits new drug application for once-daily post-cataract surgery NSAID

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif., — Ista Pharmaceuticals has submitted a new drug application to the U.S. Food and Drug Administration seeking approval to market its bromfenac ophthalmic solution drug as a once-daily treatment for inflammation, pain and photophobia after cataract surgery, the company announced in a press release.

Xibrom (bromfenac ophthalmic solution) is a topical nonsteroidal anti-inflammatory drug compound indicated for treating ocular inflammation and pain. It was approved in 2005 and is the only FDA-approved twice-daily NSAID indicated for treating post-cataract surgery inflammation and pain, according to the release.